
The Chemours Company (NYSE:CC – Free Report) – Equities research analysts at Zacks Research reduced their Q1 2027 earnings per share (EPS) estimates for Chemours in a report issued on Monday, November 16th. Zacks Research analyst Team now forecasts that the specialty chemicals company will post earnings per share of $0.21 for the quarter, down from their previous forecast of $0.40. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Chemours’ FY2027 earnings at $1.71 EPS and FY2028 earnings at $1.98 EPS.
Chemours (NYSE:CC – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the firm earned $0.40 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis.
View Our Latest Analysis on Chemours
Chemours Stock Down 2.5%
NYSE:CC opened at $11.78 on Wednesday. The firm has a market cap of $1.77 billion, a P/E ratio of -11.55 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The firm has a 50-day simple moving average of $13.50 and a two-hundred day simple moving average of $18.09.
Chemours Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is presently -34.31%.
Hedge Funds Weigh In On Chemours
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Chemours during the 2nd quarter valued at $477,769,000. Wolf Hill Capital Management LP purchased a new stake in shares of Chemours in the 2nd quarter worth $59,698,056. Goldman Sachs Group Inc. increased its stake in shares of Chemours by 10.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,838,890 shares of the specialty chemicals company’s stock worth $38,524,000 after purchasing an additional 276,451 shares in the last quarter. Jefferies Financial Group Inc. raised its holdings in Chemours by 251.8% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock worth $37,210,000 after purchasing an additional 1,962,523 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Chemours in the 2nd quarter worth $33,353,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.
Chemours News Roundup
Here’s some of the latest news about CC:
- Neutral Sentiment: Chemours announced that General Counsel Kristine Wellman will retire and that Amy Rocklin will succeed her, effective January 4, 2027. The planned transition does not include a stated change to strategy or financial outlook. Article: Chemours announces General Counsel retirement and appointment
- Negative Sentiment: Several law firms reiterated that investors have until December 7, 2026, to seek lead-plaintiff status in a securities class action covering purchases from February 20 through August 4, 2026. The complaint alleges Chemours overstated aftermarket demand for its Opteon refrigerants and maintained 2026 guidance without accounting for sales pulled forward by distributor stocking in 2025. These are allegations, not proven findings, but the case may add legal and reputational uncertainty. Article: Chemours shareholder alert on securities lawsuit
- Negative Sentiment: Zacks Research cut its estimates for Chemours’ Q1 2027 EPS to $0.21 from $0.40, FY2027 EPS to $1.71 from $2.05, and FY2028 EPS to $1.98 from $2.31. Its “Strong Sell” rating and lower profit forecasts could weigh on sentiment by signaling weaker expected earnings. Article: Zacks Research estimates Chemours’ FY2026 earnings
Chemours Company Profile
The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.
Recommended Stories
- Five stocks we like better than Chemours
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
